Study to Measure Impact of ProstaScint Imaging in Prostate Cancer
PRINCETON, New Jersey-Cytogen Corporation’s ProstaScint (capromab pendetide) is being evaluated in a phase I/II clinical study for its utility in helping guide intensity modulated radiation therapy (IMRT) for prostate cancer.
PRINCETON, New JerseyCytogen Corporation’s ProstaScint (capromabpendetide) is being evaluated in a phase I/II clinical study for its utility inhelping guide intensity modulated radiation therapy (IMRT) for prostate cancer.
ProstaScint is a radiolabeled monoclonal antibody that targets prostate specificmembrane antigen. In the study, the specific areas of greatest tumor burdenwithin the prostate, identified by the ProstaScint image, will receive boosteddoses of radiation via IMRT.
Articles in this issue
Translational Research, Early Clinical Trials Support Xeloda/RT in GI Cancers
Capecitabine Research Points to New Combinations for Metastatic Breast Cancer
Good Activity for Capecitabine Confirmed in European Study
European Data Support Benefit of Capecitabine/Irinotecan Regimen in Advanced Colorectal Cancer Patients
Single-Agent Capecitabine May Benefit Elderly Colorectal Cancer Patients
Single-Agent Sequential Rx May Be Reasonable for Metastatic Breast Cancer
Intermittent R115777 Equally Effective but Better Tolerated in Breast Cancer Patients
Carboplatin/Vinorelbine/Capecitabine Active in Pretreated Metastatic Breast Cancer
Longer Survival With FOLFOX4 in Metastatic Colorectal Cancer Patients
Capecitabine/Vinorelbine Effective in Heavily Pretreated Patients
Oral Regimen of UFT/Leucovorin and Etoposide Shows Promising Results
Docetaxel/Capecitabine Bests Single-Agent Docetaxel in Metastatic Breast Cancer
COX-2 Inhibitor May Boost Capecitabine Response
Celecoxib Added to IFL Reduces Toxicity in Patients With Metastatic Colorectal Cancer
Irinotecan Every 2 Weeks With Capecitabine Is Well Tolerated
Recent Videos
Related Content
